NovaBridge Biosciences (NBP) EBT Margin (2023)

NovaBridge Biosciences (NBP) reported EBT Margin of 738200.0% for Q4 2023, down 28185.25% quarter-over-quarter from 2609.84% in Q3 2023.

NovaBridge Biosciences (NBP) EBT Margin (2023) Analysis & Trends

NovaBridge Biosciences (NBP) has 1 years of EBT Margin data on file, last reported at 738200.0% in Q4 2023.

EBT Margin for Q4 2023 came in at 738200.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 4361.77% (changed N/A YoY), and the FY2023 annual result was 13009.02%, down 391166.0% from the prior year.
EBT Margin eased to 738200.0% in Q4 2023 per NBP's latest filing, from 2609.84% in the prior quarter.
Over five years, EBT Margin peaked at 2609.84% in Q3 2023 and troughed at 738200.0% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	6.40%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	41.95%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	NovaBridge Biosciences	328.19 Mn	117.34 Mn	-	-

Download Data